Christopher Kimball

Cooley advised TBO, a leading global travel distribution platform, on its agreement to acquire Classic Vacations from Arizona-based investment firm, the Najafi Companies.

Cooley advised Framer, a professional website design platform that has quickly become the platform of choice for companies that want to ship their entire .com, on its $100 million Series D financing.

Cooley advised Group14 Technologies, a global leader in advanced silicon battery materials, on the close of its $463 million Series D financing and acquisition of its joint venture with SK, Inc.

Cooley advised a syndicate of globally recognized private and public investors in connection with the management-led majority stake acquisition of HistoSonics, the developer of the Edison Histotripsy System and novel histotripsy therapy platform, valuing the company at approximately $2.25 billion.

Cooley advised Y-mAbs Therapeutics, a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer, on its definitive merger agreement with SERB Pharmaceuticals. Under the agreement, SERB will acquire Y-mAbs, including its lead commercial oncology asset, DANYELZA, in an all-cash transaction representing an equity value of approximately $412 million.